Brooks Laboratories Limited
NSE: BROOKS BSE: BROOKS
NSE
125.68
-0.32 (-0.25%)
Prev Close
126
Open Price
121.01
Volume
25,813
Today Low / High
121.01 / 126.75
52 WK Low / High
82 / 198.86
Range
119 - 132
BSE
124.90
-0.60 (-0.48%)
Prev Close
125.5
Open Price
126
Volume
3,807
Today Low / High
124 / 127.9
52 WK Low / High
82.25 / 202.8
Range
119 - 131
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 125.68 (target range: 119 - 132), reflecting a change of -0.32 (-0.25397%). On the BSE, it is listed at 124.9 (target range: 119 - 131), showing a change of -0.6 (-0.47809%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
13 Jun
121.01
3.86%
12 Jun
129.00
-2.33%
11 Jun
129.13
-0.86%
10 Jun
131.85
-2.06%
09 Jun
130.20
0.38%
06 Jun
139.29
-4.58%
05 Jun
144.67
-4.25%
04 Jun
151.44
-4.94%
03 Jun
148.86
-1.13%
02 Jun
143.33
3.86%
30 May
143.33
0.00%
29 May
130.01
5.00%
28 May
131.50
-1.13%
27 May
135.90
-2.75%
26 May
134.05
0.18%
23 May
134.00
0.29%
22 May
137.59
-1.96%
21 May
136.99
-0.39%
20 May
138.00
-1.95%
19 May
139.80
-2.81%
Brooks Laboratories Limited Graph
Brooks Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Brooks Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 125.68, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 124.90 | 126.15 | 113.53 - 138.76 |
| 127.40 | 101.92 - 152.88 | ||
| 128.65 | 90.05 - 167.24 | ||
| Bearish Scenario | 124.90 | 123.65 | 111.29 - 136.02 |
| 122.40 | 97.92 - 146.88 | ||
| 121.15 | 84.81 - 157.50 |
Overview of Brooks Laboratories Limited
ISIN
INE650L01011
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
49,899
Market Cap
3,702,180,896
Last Dividend
0
Official Website
IPO Date
2011-09-05
DCF Diff
240.17
DCF
-114
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 82.56 Cr | 68.63 Cr | 13.92 Cr | 0.1686 | 0.00 Cr | 0.00 Cr | 3.34 Cr | -9.97 Cr | -3.72 | 5.82 Cr | -0.1207 |
| 2024-03-31 | 79.01 Cr | 72.92 Cr | 6.09 Cr | 0.0770 | 0.00 Cr | 4.37 Cr | 1.44 Cr | -19.59 Cr | -7.65 | 4.17 Cr | -0.2480 |
| 2023-03-31 | 63.20 Cr | 50.60 Cr | 12.60 Cr | 0.1994 | 0.00 Cr | 10.09 Cr | -33.40 Cr | -20.90 Cr | -8.38 | -29.17 Cr | -0.3307 |
| 2022-03-31 | 90.09 Cr | 75.80 Cr | 14.29 Cr | 0.1587 | 0.00 Cr | 8.84 Cr | -21.38 Cr | -19.31 Cr | -7.74 | -13.45 Cr | -0.2144 |
| 2021-03-31 | 77.07 Cr | 55.24 Cr | 21.83 Cr | 0.2832 | 0.00 Cr | 6.55 Cr | -6.57 Cr | -19.38 Cr | -7.77 | 1.25 Cr | -0.2514 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.25 Cr | 123.69 Cr | 25.59 Cr | 98.1043 Cr | 7.58 Cr | 6.33 Cr | 9.20 Cr | 13.97 Cr | 0.00 Cr | 0.00 Cr | 73.69 Cr | 22.8441 Cr |
| 2024-03-31 | 0.13 Cr | 90.45 Cr | 24.86 Cr | 65.5853 Cr | 5.64 Cr | 5.52 Cr | 9.61 Cr | 13.60 Cr | 0.26 Cr | 0.00 Cr | 42.91 Cr | 23.0476 Cr |
| 2023-03-31 | 0.02 Cr | 109.60 Cr | 35.64 Cr | 73.9532 Cr | 6.51 Cr | 6.49 Cr | 11.30 Cr | 14.81 Cr | 2.60 Cr | 0.00 Cr | 64.19 Cr | 33.0213 Cr |
| 2022-03-31 | 2.61 Cr | 195.91 Cr | 61.59 Cr | 63.0508 Cr | 25.26 Cr | 22.65 Cr | 27.52 Cr | 124.49 Cr | 3.58 Cr | -5.37 Cr | 0.28 Cr | 48.8783 Cr |
| 2021-03-31 | 0.88 Cr | 162.08 Cr | 82.93 Cr | 79.1484 Cr | 31.38 Cr | 30.50 Cr | 23.60 Cr | 107.70 Cr | 14.56 Cr | 15.98 Cr | 0.33 Cr | 63.7142 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.7623 Cr | -46.0409 Cr | 44.1965 Cr | -0.0971 Cr | 0.0000 Cr | 1.2480 Cr | -1.8594 Cr | -9.9670 Cr | 1.0213 Cr | 0.0000 Cr | 0.4060 Cr |
| 2024-03-31 | -9.6806 Cr | 0.1822 Cr | 9.6007 Cr | -10.1196 Cr | 0.1023 Cr | 0.1255 Cr | -0.4390 Cr | -19.5919 Cr | -0.8703 Cr | 0.0000 Cr | 1.6923 Cr |
| 2023-03-31 | -14.4906 Cr | 0.4948 Cr | 11.4140 Cr | -14.9581 Cr | -2.5818 Cr | 0.0232 Cr | -0.4675 Cr | -35.4251 Cr | -4.0322 Cr | 0.0000 Cr | 3.2860 Cr |
| 2022-03-31 | -37.4407 Cr | -24.9086 Cr | 64.0706 Cr | -65.0530 Cr | 1.7211 Cr | 2.6050 Cr | -27.6123 Cr | -23.8977 Cr | -7.2510 Cr | 0.0000 Cr | -3.9193 Cr |
| 2021-03-31 | 4.4587 Cr | -5.1296 Cr | 1.1589 Cr | -1.1551 Cr | 0.4880 Cr | 0.8839 Cr | -5.6138 Cr | -8.9933 Cr | 4.3813 Cr | 0.0000 Cr | -9.8282 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 23.32 Cr | 19.58 Cr | 3.74 Cr | 0.1602 | 1.15 Cr | -1.46 Cr | -0.54 | 2.16 Cr | -0.0625 |
| 2024-12-31 | 38.45 Cr | 25.06 Cr | 13.38 Cr | 0.3481 | 1.07 Cr | -4.57 Cr | -1.51 | -3.32 Cr | -0.1189 |
| 2024-09-30 | 20.79 Cr | 13.20 Cr | 7.59 Cr | 0.3653 | 1.08 Cr | -3.96 Cr | -1.51 | -3.21 Cr | -0.1906 |
| 2024-06-30 | 17.93 Cr | 12.31 Cr | 5.63 Cr | 0.3138 | -4.93 Cr | -2.41 Cr | -0.94 | -1.85 Cr | -0.1346 |
| 2024-03-31 | 17.72 Cr | 15.45 Cr | 2.27 Cr | 0.1281 | -0.08 Cr | -9.61 Cr | -3.77 | 1.03 Cr | -0.5420 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.25 Cr | 0.00 Cr | 1.25 Cr | 19.99 Cr | 9.20 Cr | 33.88 Cr | 13.97 Cr | 123.69 Cr | 25.59 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 0.81 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -59.21 Cr |
| 2024-09-30 | 0.17 Cr | 2.18 Cr | 2.35 Cr | 0.00 Cr | 9.48 Cr | 37.86 Cr | 14.55 Cr | 91.12 Cr | 31.92 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 0.69 Cr | 0.00 Cr | 0.00 Cr | 0.69 Cr | 0.00 Cr | 0.00 Cr | -65.59 Cr |
| 2024-03-31 | 0.69 Cr | 2.33 Cr | 0.69 Cr | 16.32 Cr | 9.61 Cr | 31.05 Cr | 13.60 Cr | 90.45 Cr | 24.86 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | -4.57 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | -3.96 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | -2.41 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | -9.61 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | -3.88 Cr | 0.87 Cr | 0.00 Cr | 0.00 Cr | 0.87 Cr | 1.37 Cr | 0.50 Cr | 0.00 Cr | 0.87 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2020-02-11 | February 11, 20 | 1199:1000 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,687.80 | ₹4,049,504,784,000.00 | ₹2,404,272.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,667.00 | ₹1,769,881,823,000.00 | ₹431,430.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,362.50 | ₹1,133,629,620,750.00 | ₹1,419,556.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,252.50 | ₹1,100,792,362,500.00 | ₹412,987.00 |
| Mankind Pharma Limited | MANKIND | ₹2,381.30 | ₹982,693,571,365.00 | ₹192,187.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹974.95 | ₹981,023,938,500.00 | ₹1,046,498.00 |
| Lupin Limited | LUPIN | ₹1,999.60 | ₹913,207,322,000.00 | ₹475,900.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,150.20 | ₹668,038,460,400.00 | ₹1,133,056.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,847.50 | ₹579,591,337,500.00 | ₹382,701.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,669.90 | ₹471,247,449,900.00 | ₹937,744.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹1,004.50 | ₹384,288,559,536.00 | ₹284,738.00 |
| Laurus Labs Limited | LAURUSLABS | ₹666.60 | ₹359,466,049,800.00 | ₹1,292,254.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,368.40 | ₹347,168,553,600.00 | ₹279,721.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,634.20 | ₹329,043,190,400.00 | ₹135,145.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,776.20 | ₹288,595,199,800.00 | ₹1,424,706.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,734.40 | ₹270,521,305,600.00 | ₹148,082.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹10,509.50 | ₹262,737,500,000.00 | ₹106,451.00 |
| Piramal Enterprises Limited | PEL | ₹1,132.60 | ₹256,735,502,800.00 | ₹286,201.00 |
| Eris Lifesciences Limited | ERIS | ₹1,795.10 | ₹244,465,693,500.00 | ₹274,234.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹999.10 | ₹196,386,093,300.00 | ₹47,032.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,094.20 | ₹174,285,270,200.00 | ₹6,466,031.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,193.00 | ₹169,264,870,700.00 | ₹58,120.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹912.70 | ₹163,473,697,000.00 | ₹1,294,720.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,140.30 | ₹162,687,841,510.00 | ₹113,463.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹509.40 | ₹123,551,913,600.00 | ₹1,034,675.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,831.00 | ₹96,791,101,400.00 | ₹9,403.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹985.80 | ₹96,402,269,220.00 | ₹608,474.00 |
| Strides Pharma Science Limited | STAR | ₹882.45 | ₹81,328,974,615.00 | ₹737,669.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹885.65 | ₹80,270,551,203.00 | ₹275,301.00 |
| FDC Limited | FDC | ₹475.85 | ₹77,473,138,500.00 | ₹335,602.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹165.90 | ₹53,838,199,800.00 | ₹784,168.00 |
| Innova Captab Limited | INNOVACAP | ₹907.30 | ₹51,920,178,989.00 | ₹790,854.00 |
| Suven Life Sciences Limited | SUVEN | ₹236.03 | ₹51,472,006,220.00 | ₹2,123,847.00 |
| Sequent Scientific Limited | SEQUENT | ₹197.26 | ₹49,374,572,520.00 | ₹872,716.00 |
| Hikal Limited | HIKAL | ₹375.80 | ₹46,336,515,800.00 | ₹173,076.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹606.10 | ₹42,672,955,380.00 | ₹100,232.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹463.75 | ₹42,326,462,500.00 | ₹202,711.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,341.50 | ₹38,726,068,500.00 | ₹63,054.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹370.65 | ₹37,168,040,700.00 | ₹24,849.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹714.10 | ₹36,218,509,310.00 | ₹99,610.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹64.67 | ₹35,436,185,180.00 | ₹4,993,774.00 |
| Alembic Limited | ALEMBICLTD | ₹115.66 | ₹29,699,406,004.00 | ₹924,689.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹88.75 | ₹26,050,521,250.00 | ₹694,137.00 |
| Indoco Remedies Limited | INDOCO | ₹280.70 | ₹25,893,985,530.00 | ₹64,810.00 |
Key Executives
President of Procurement
Mr. Rajesh Mahajan MBA
Gender: male
Year Born: 1969
Company Secretary & Compliance Officer
Ms. Krutika Mohan Rane
Gender: female
Year Born: 1993
Whole-Time Director
Mr. Bhushan Singh Rana
Gender: male
Year Born: 1955
Vice President of Sales & Marketing
Nikhil Anand Verma
Gender: Not Specified
Year Born: 1964
President of Corporate Strategy
Mr. Atul Ranchal PGDFMT
Gender: male
Year Born: 1967
Whole Time Director
Dr. Durga Shankar Maity M.Sc.
Gender: Not Specified
Year Born: 1964
Whole Time Director
Mr. Jitendra Pratap Singh
Gender: male
Year Born: 1974
Chief Financial Officer
Mr. Prashant Rathi
Gender: male
Year Born: 1991
FAQs about Brooks Laboratories Limited
Who is the CEO of the company?
The CEO is Mr. Prashant Rathi.
What is the current market price of the stock?
The current price is ₹125.68.
What is the 52-week price range?
The range is ₹82-198.86.
What is the market capitalization of the company?
The market capitalization is ₹370.22 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is -27.76.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Brooks Laboratories Limited (ISIN: INE650L01011) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹370.22 crores and an average daily volume of 49,899 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.